Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Kineret (anakinra)

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    69 result(s) found for: Kineret (anakinra). Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2015-004393-16 Sponsor Protocol Number: NL55231.041.15 Start Date*: 2016-10-04
    Sponsor Name:University Medical Center Utrecht
    Full Title: Biomarker-guided treatment-and-stop-strategy for recombinant IL-1receptor antagonist (anakinra) in patients with systemic Juvenile Idiopathic Arthritis.
    Medical condition: systemic Juvenile Idiopathic Arthritis
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004292-69 Sponsor Protocol Number: MEFV01 Start Date*: 2016-01-12
    Sponsor Name:UZ Leuven
    Full Title: Anakinra (Kineret®) for a hereditary autoinflammatory disease with MEFV mutation and inflammasome activation.
    Medical condition: hereditary autoinflammatory disease with MEFV mutation and inflammasome activation
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003683-28 Sponsor Protocol Number: SI003-001 Start Date*: 2022-07-28
    Sponsor Name:SelectImmune Pharma AB
    Full Title: Kineret for the treatment of Bladder Pain Syndrome (BPS). Randomized, double-blind, cross-over, phase II trial.
    Medical condition: Patients diagnosed with Bladder Pain Syndrome (BPS)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001167-93 Sponsor Protocol Number: Sobi.IMMUNO-101 Start Date*: 2020-03-27
    Sponsor Name:SWEDISH ORPHAN BIOVITRUM AB (PUBL)
    Full Title: A phase 2/3, randomized, open-label, parallel group, 3-arm, multicenter study investigating the efficacy and safety of intravenous administrations of emapalumab, an anti-interferon gamma (anti-IFN¿...
    Medical condition: SARS-CoV-2 infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001636-95 Sponsor Protocol Number: 282110 Start Date*: 2020-05-20
    Sponsor Name:University of Manchester
    Full Title: Subcutaneous and Intravenous anakinra in COVID-19 Infection - Feasibility & Pharmacokinetics/ Pharmacodynamics study
    Medical condition: Suspected or confirmed SARS-CoV-2 infection (confirmed by RNA-PCR)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-005402-65 Sponsor Protocol Number: IIBSP-ANA-2013-163 Start Date*: 2015-01-19
    Sponsor Name:Institut de Recerca HSCSP
    Full Title: Efficacy and safety of anakinra (antagonist of the interleukin-1 receptor) in the treatment of periarticular inflammation in patients refractory to NSAID and / or steroids
    Medical condition: Inflammation in periarticular structures in patients refractory to NSAIDs and / or corticosteroids.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003433-20 Sponsor Protocol Number: P150921 Start Date*: 2016-12-16
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Anakinra versus placebo double blind Randomized controlled trial for the treatment of Acute Myocarditis
    Medical condition: Patients hospitalized for Acute myocarditis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004849 10000932 Acute myocarditis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000324-36 Sponsor Protocol Number: NL76607.091.21 Start Date*: 2022-03-21
    Sponsor Name:Radboudumc
    Full Title: Anakinra in Cerebral haemorrhage to Target secondary Injury resulting from Neuroinflammation - a phase II clinical trial
    Medical condition: Spontaneous supratentorial intracerebral haemorrhage
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-019218-26 Sponsor Protocol Number: ANA-ALS01 Start Date*: 2010-12-06
    Sponsor Name:Charité - University Hospital of Berlin
    Full Title: Offene Verträglichkeitsstudie zur Evaluierung einer subkutanen Injektionslösung von 100 mg Anakinra in Kombination mit Riluzol bei Patienten mit Amyotropher Lateralsklerose (ALS).
    Medical condition: Amyotophic lateral sclerosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004089-16 Sponsor Protocol Number: 1541-128 Start Date*: 2013-04-03
    Sponsor Name:Universitätsklinik für Innere Medizin III, Klinische Abteilung für Rheumatologie, Medizinische Universität Wien
    Full Title: The effect of the interleukin-1 receptor antagonist Anakinra in patients with osteoarthritis of the hand: The AHOA (Anakinra in hand osteoarthritis) pilot study
    Medical condition: osteoarthritis of the hand
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003028-59 Sponsor Protocol Number: NL62684.091.17 Start Date*: 2018-06-06
    Sponsor Name:Radboud University Medical Centre
    Full Title: Treatment with Recombinant human Interleukin 1 receptor antagonist (Anakinra) in patients with Anaplastic Thyroid Cancer: a proof of concept study
    Medical condition: Anaplastic Thyroid Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-019660-36 Sponsor Protocol Number: Anakinra1 Start Date*: 2010-12-07
    Sponsor Name:UMC St Radboud
    Full Title: The effect of interleukin-1 receptor antagonist on insulin secretion
    Medical condition: Beta-cell dysfunction
    Disease: Version SOC Term Classification Code Term Level
    12.1 10052341 Impaired insulin secretion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-003725-42 Sponsor Protocol Number: R121178 Start Date*: 2018-03-23
    Sponsor Name:University of Manchester
    Full Title: Does Interleukin-1 Receptor Antagonist Improve Outcome following aneurysmal Subarachnoid Haemorrhage (aSAH)? A Phase III trial
    Medical condition: subarachnoid haemorrhage
    Disease: Version SOC Term Classification Code Term Level
    20.1 10022117 - Injury, poisoning and procedural complications 10042316 Subarachnoid haemorrhage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-004786-80 Sponsor Protocol Number: ANAKIN Start Date*: 2019-02-20
    Sponsor Name:Ruprecht-Karls-University Heidelberg, Medical Faculty
    Full Title: A phase IIa, randomized, placebo-controlled, double-blind, cross-over study to evaluate safety and efficacy of subcutanous administration of anakinra in patients with cystic fibrosis.
    Medical condition: Cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10028141 Mucoviscidosis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-005046-10 Sponsor Protocol Number: HEMSC42 Start Date*: 2019-07-23
    Sponsor Name:Radboud university medical center
    Full Title: Anakinra: Efficacy of interleukin-1 pathway inhibitor anakinra for the management of fever during neutropenia and mucositis in patients with multiple myeloma receiving an autologous hematopoietic s...
    Medical condition: Febrile neutropenia and mucositis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004867 10028127 Mucositis LLT
    20.0 10005329 - Blood and lymphatic system disorders 10016288 Febrile neutropenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000300-42 Sponsor Protocol Number: 03AR0298 Start Date*: 2013-01-18
    Sponsor Name:National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
    Full Title: A long-term outcome study with the IL-1 receptor antagonist Anakinra/Kineret® in patients with Neonatal onset multisystem inflammatory disease (Nomid/Cinca syndrome)
    Medical condition: neonatal onset multisystem inflammatory disease (NOMID/CINCA)
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-003173-24 Sponsor Protocol Number: AOSD Study 05 Start Date*: 2005-12-22
    Sponsor Name:Helsinki University Central Hospital
    Full Title: An open, randomized study treating refractory adult-onset Still´s disease (AOSD) with interleukin-1 receptor antagonist anakinra (KineretR), compared to an established, single anti-rheumatic drug t...
    Medical condition: Refractory adult onset Still´s disease (AOSD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Ongoing) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005079-32 Sponsor Protocol Number: 00001 Start Date*: 2007-12-04
    Sponsor Name:Medical University of Vienna
    Full Title: Treatment of secondary renal amyloidosis A with the Intereleukin – 1 antagonist anakinra
    Medical condition: Renal Amyloidosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003472-13 Sponsor Protocol Number: MYTH-1 Start Date*: 2019-10-31
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Myocarditis Therapy with IL-1 inhibitor (MYTH-1): a double-blind, phase IIa, placebo-controlled, randomized clinical trial to evaluate the efficacy and safety of anakinra in addition to standard of...
    Medical condition: Endomyocardial biopsy proven virus-negative myocarditis with left ventricular ejection fraction lower than 55%.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10007541 - Cardiac disorders 10064539 Autoimmune myocarditis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-002337-36 Sponsor Protocol Number: 2007neuro07/R013630/S1 Start Date*: 2008-06-06
    Sponsor Name:Salford Royal NHS Foundation Trust
    Full Title: An open-labelled study of the cerebrospinal fluid pharmacokinetics of intravenous Kineret® in patients with subarachnoid haemorrhage
    Medical condition: This is a pharmacokinetic study in patients who have had a Subarachnoid Haemorrhage and who have had an external ventricular drain inserted for clinical management reasons, must usually for the tre...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042316 Subarachnoid haemorrhage LLT
    9.1 10052947 Ventricular drainage LLT
    9.1 10020508 Hydrocephalus LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 08:19:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA